Literature DB >> 2125394

Pharmacoeconomics: therapeutic and economic considerations in treating the critically ill patient.

V S Crane1.   

Abstract

The critically ill patient is at high risk for developing complications and, consequently, higher costs of treatment. Because of the high costs associated with these patients, healthcare payers are demanding the development of criteria to ensure cost-effective care. Pharmacists can play an important role in ensuring cost-effective and appropriate care of critically ill patients. The length of hospital stay, the single most important variable influencing the overall cost of patient care, is increased by lack of a structured patient management plan and by the development of complications. Many of these complications are preventable by appropriate drug therapy and monitoring, thus representing the cost factor most controllable by pharmacists. Pharmacists can use newer tools such as cost-effective analysis and clinical decision analysis to identify and utilize drug therapies that result in decreased complications and decreased length of hospital stay, as measured by decreased costs. Equally important is the development of criteria for the appropriate use of drug therapies. Pharmacists must take an active role in working with physicians, nurses, payers, and risk managers.

Entities:  

Mesh:

Year:  1990        PMID: 2125394

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  5 in total

1.  Cost-effective prescribing in elderly people.

Authors:  D J Morgan; C A Sutters; B Livesley
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

2.  Identifying drug usage patterns in the intensive care unit.

Authors:  H J Mann; E T Wittbrodt
Journal:  Pharmacoeconomics       Date:  1993-10       Impact factor: 4.981

3.  Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma.

Authors:  E Souêtre; W Qing
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

4.  Assessing antibacterial pharmacoeconomics in the intensive care unit.

Authors:  M C Birmingham; J M Hassett; J J Schentag; J A Paladino
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

5.  Economic study of neutropenia induced by myelotoxic chemotherapy.

Authors:  M C Montero; M L Valdivia; E Carvajal; A Montaño; C Buenestado; A Lluch; M Atienza
Journal:  Pharm World Sci       Date:  1994-08-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.